- 全部删除
- 您的购物车当前为空
(S)-p38 MAPK inhibitor III is a methylsulfanylimidazole that inhibits p38 MAP kinase (IC50 = 0.90 μM in vitro). It is cell-permeable, potently blocking the release of TNF-α and IL-1β from human peripheral blood mononuclear cells (IC50s = 0.37 and 0.044 μM, respectively).
(S)-p38 MAPK inhibitor III is a methylsulfanylimidazole that inhibits p38 MAP kinase (IC50 = 0.90 μM in vitro). It is cell-permeable, potently blocking the release of TNF-α and IL-1β from human peripheral blood mononuclear cells (IC50s = 0.37 and 0.044 μM, respectively).
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
500 μg | 待估 | 35日内发货 | |
1 mg | 待估 | 35日内发货 | |
5 mg | 待估 | 35日内发货 | |
10 mg | 待估 | 35日内发货 |
产品描述 | (S)-p38 MAPK inhibitor III is a methylsulfanylimidazole that inhibits p38 MAP kinase (IC50 = 0.90 μM in vitro). It is cell-permeable, potently blocking the release of TNF-α and IL-1β from human peripheral blood mononuclear cells (IC50s = 0.37 and 0.044 μM, respectively). |
靶点活性 | p38 MAP kinase:0.9 μM |
别名 | (S)-p38 MAPK Inhibitor III |
分子量 | 404.5 |
分子式 | C23H21FN4S |
CAS No. | 581098-48-8 |
密度 | 1.30 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
溶解度信息 | DMSO: 12 mg/mL (29.67 mM), Sonication is recommended. Ethanol: 30 mg/mL (74.17 mM), Sonication is recommended. Ethanol:PBS (pH 7.2)(1:2): 0.33 mg/mL (0.82 mM), Sonication is recommended. DMF: 20 mg/mL (49.44 mM), Sonication is recommended. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容